Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context

Toshihiro Matsukawa1 | Mianmian Yin1 | Timour Baslan2 | Yang Jo Chung1 | Dengchao Cao1 | Ryan Bertoli1 | Yuelin J. Zhu1 | Robert L. Walker1 | Amy Freeland3 | Erik Knudsen3 | Scott W. Lowe2,4 | Paul S. Meltzer1 | Peter D. Aplan1

1Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2Cancer Biology and Genetics Program, Sloan-Kettering Institute, New York, New York, USA
3Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York, USA
4Howard Hughes Medical Institute, Chevy Chase, Maryland, USA

Correspondence
Peter D. Aplan, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37 Room 6002, 37 Convent Drive, Bethesda, MD 20892, USA.
Email: aplanp@mail.nih.gov

Funding information
HHS | NIH | National Cancer Institute (NCI), Grant/Award Number: SC0130378 and SC010379; Memorial Sloan-Kettering Cancer Center (MSK); Naito Foundation; Uehara Memorial Foundation

Abstract
Minichromosome maintenance proteins (Mcm2-7) form a hexameric complex that unwinds DNA ahead of a replicative fork. The deficiency of Mcm proteins leads to replicative stress and consequent genomic instability. Mice with a germline insertion of a Cre cassette into the 3'UTR of the Mcm2 gene (designated Mcm2Cre) have decreased Mcm2 expression and invariably develop T-cell lymphoblastic leukemia/lymphoma (pre-T LBL), due to 100–1000 kb deletions involving important tumor suppressor genes. To determine whether mice that were protected from pre-T LBL would develop non-T-cell malignancies, we used two approaches. Mice engrafted with Mcm2Cre/Cre Lin-Sca-1+Kit+ hematopoietic stem/progenitor cells did not develop hematologic malignancy; however, these mice died of hematopoietic stem cell failure by 6 months of age. Placing the Mcm2Cre allele onto an athymic nu/nu background completely prevented pre-T LBL and extended survival of these mice three-fold (median 296.5 vs. 80.5 days). Ultimately, most Mcm2Cre/Cre;nu/nu mice developed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We identified recurrent deletions of 100–1000 kb that involved genes known or suspected to be involved in BCP-ALL, including Pax5, Nf1, Ikar, and Bcor. Moreover, whole-exome sequencing identified recurrent mutations of genes known to be involved in BCP-ALL progression, such as Jak1/Jak3, Ptpn11, and Kras. These findings demonstrate that an Mcm2Cre/Cre hypomorph can induce hematopoietic dysfunction via hematopoietic stem cell failure as well as a “deleter” phenotype affecting known or suspected tumor suppressor genes.

KEYWORDS
B-cell precursor acute lymphoblastic leukemia, bone marrow failure, DNA stress, Mcm2, tumor suppressor gene

Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; pre-T LBL, precursor T-cell lymphoblastic leukemia/lymphoma; MCM, Minichromosome maintenance.

Toshihiro Matsukawa and Mianmian Yin contributed equally to this work.

© 2022 Federation of American Societies for Experimental Biology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
1 | INTRODUCTION

DNA replication is a semi-conservative process in which daughter cell DNA is synthesized from a parental cell DNA template. Eukaryotic DNA replication initiates with duplication of chromosomal DNA via the formation of a DNA replication “bubble” and bidirectional replication forks. Minichromosome maintenance (MCM) proteins 2–7 form a hexameric complex that is loaded onto parental DNA at the origin of DNA replication as a double hexamer in late M and G1 phases. The MCM2-7 complex functions as a DNA helicase that unwinds parental DNA in advance of replicative polymerase and is essential for initiating DNA replication in S phase.

We and others have previously reported that a mouse with an IRES-CreERT2 cassette “knocked into” the 3’UTR of the endogenous murine Mcm2 locus (Mcm2<sup>IRES-CreERT2</sup>, hereafter designated Mcm2<sup>Cre</sup>) results in decreased Mcm2 expression, such that Mcm2<sup>Cre</sup> mice have 20–30% the amount of Mcm2 protein compared to wild-type (WT) controls. Almost all Mcm2<sup>Cre</sup> mice developed a lethal precursor T-cell lymphoblastic leukemia/lymphoma (pre-T LBL) within 4 months of life. Close analysis of these pre-T LBL revealed that the tumors had undergone 50–1000 kb interstitial deletions of genes well known to be important for mouse and human pre-T LBL, including PTEN, NOTCH1, and TCF3. The precise mechanism that causes these interstitial deletions in Mcm2<sup>Cre</sup> pre-T LBL remains unknown, but it is suspected that limiting amounts of Mcm2 protein lead to replication fork collapse and subsequent DNA double-strand breaks (DSB) at the site of replication fork collapse. Repair of two contiguous DNA DSB formed after replication fork collapse, via non-homologous end-joining (NHEJ), leads to the interstitial deletion.

We hypothesized that this unique “deleter” phenotype could be a generally useful mechanism for identifying tumor suppressor genes. However, Mcm2<sup>Cre/Cc</sup> mice that were predisposed to acute myeloid leukemia (AML) through the addition of a NUP98-HOXD13 (NDH13) transgene, which has been shown to induce myelodysplastic syndrome (MDS) and AML, did not develop AML. Instead, the Mcm2<sup>Cre/Cc;NDH13</sup> developed pre-T LBL at the same age as Mcm2<sup>Cre/Cc</sup> mice. We suspected that the highly penetrant pre-T LBL phenotype was lethal to the mice before a less aggressive malignancy could develop, thus obscuring any AML that might develop in Mcm2<sup>Cre/Cc;NDH13</sup> mice. As detailed herein, we used several complementary approaches to test the hypothesis that if Mcm2<sup>Cre/Cc</sup> mice were prevented from developing pre-T LBL, we could uncover alternate forms of malignancy in Mcm2<sup>Cre/Cc</sup> mice. The techniques we evaluated to prevent pre-T LBL included allogeneic bone marrow transplantation, and crosses with T-cell-deficient mouse strains. In addition, we describe an attempt to generate AML, through crossing Mcm2<sup>Cre/Cc</sup> mice to a mouse strain that is predisposed to develop AML.

2 | MATERIALS AND METHODS

2.1 | Mouse strains and genotyping

Mcm2<sup>Cre/Cc</sup>, NUP98-PHF23 (NP23), and NDH13 single transgenic mice were generated on a C57BL/6 background as previously reported. Mcm2<sup>Cre/Cc</sup>;NP23 or Mcm2<sup>Cre/Cc;NDH13</sup> double transgenic mice were generated by crossing the NP23 or NDH13 transgenes onto a Mcm2<sup>Cre/Cc</sup> background. The Foxn1<sup>nu</sup> (nu/nu) athymic nude mutation arose in a mouse stock that was closed but not inbred, and was subsequently bred for at least 100 generations before purchase from the Jackson Laboratory. Prkdc<sup>scid</sup> (Scid/Scid) mice on a C57BL/6 background were purchased from the Jackson Laboratory. Genotyping was performed using the primers listed (Supporting Information Table S10). The PCR reaction for Scid was digested with Alu (New England BioLabs Inc.), and WT or mutant fragments were detected using 4% agarose gel (NuSieve 3:1 Agarose; Lonza). All animal experiments were approved by the National Cancer Institute (Bethesda) Intramural Animal Care and Use Committee.

2.2 | Assessment of murine leukemia

Peripheral blood from the tail vein was periodically collected in EDTA tubes (RAM Scientific) to assess and monitor mouse health. Complete blood counts (CBCs) were measured using a HEMAVET Multispecies Hematology Analyzer (D.C. Technologies). Mice were euthanized with carbon dioxide for necropsy when they were moribund or demonstrated signs of illness such as lethargy, weight loss, kyphosis, hunched appearance, or labored breathing. Diagnosis of hematologic malignancies was based on published guidelines for mouse leukemia.

2.3 | Flow cytometry and cell sorting

Flow cytometry analyses were performed as described previously. Single cells were prepared from each tissue, resuspended with Hanks’ balanced salt solution (Lonza) with 2% fetal bovine serum (Gibco) (HF2 buffer), and stained with conjugated antibodies for 30 min on ice. The antibodies used included...
Ly-6G/Ly-6C (Gr-1)-FITC (Clone-RB6-8C5; eBioscience), CD11b (Mac-1)-PE (Clone-M1/70; eBioscience), CD8a-FITC (Clone-53-6.7; BD Biosciences), CD4-PE (Clone-GK1.5; eBioscience), CD117 (c-Kit)-FITC (Clone-2B8; eBioscience), CD117 (c-Kit)-APC/Cyanine7 (Clone-2B8; eBioscience), Ter119-FITC (Clone-TER119; BioLegend), CD71-PE (Clone-R17217; BioLegend), Ly-6A/E (Sca-1)-PE (Clone-D7; eBioscience), CD16/32-PE (Clone-93; eBioscience), CD34-FITC (Clone-SB/199; BD Biosciences), Streptavidin-PerCP/Cyanine5.5 (Clone-2B8; eBioscience), Ter119 (Clone-TER119; BD Biosciences), CD127-APC (Clone-RA3-6B2; BioLegend), CD150 (SLAM)-APC (Clone-RA3-6B2; BD Biosciences), DAPI (Cat# 64907; BD Biosciences), CD34-BV605 (Clone-M1/70; eBioscience), CD48-FITC (Clone-HM48-1; eBioscience), CD34-FITC (Clone-RAM34; BD Biosciences), CD34-BV605 (Clone-RAM34; BD Biosciences), CD127-BUV737 (Clone-SB/199; BD Biosciences), Streptavidin-PerCP/Cyanine5.5 (Cat# 8032909; BD Biosciences), Propidium Iodide (Cat# P3566; Invitrogen), CD45.2-PerCP/Cyanine5.5 (Clone-1D3; SouthernBiotech), and CD45.1-PerCP/Cyanine5.5 (Clone-104; SouthernBiotech), and CD45.2-FITC (Clone-A20; eBioscience). The stained single-cell suspension was washed twice with HF2 buffer and analyzed using FACScan (BD Biosciences), BD LSR Fortessa (BD Biosciences), or Cytek Northern Lights (Cytek) instruments.

B220-positive cells were selected using CD45R(B220) Microbeads (Miltenyi Biotec) and MACS LD column (Miltenyi Biotec) using the manufacturer’s recommended protocol. Lineage-positive cells were depleted by Lineage Cell Depletion Kit (Miltenyi Biotec) and MACS LD column (Miltenyi Biotec) using the manufacturer’s recommended protocol. Lineage-negative cells treated above were stained with appropriate antibodies and sorted with BD FACS Aria Fusion (BD Biosciences). Flow cytometry data were analyzed with FlowJo software ver 10.7.2 (BD).

2.4 | IHC and histology

Mouse tissue specimens were fixed in 10% neutral-buffered formalin (Sigma-Aldrich) and embedded in paraffin. Paraffin-fixed formalin-embedded sections were stained with hematoxylin and eosin (H&E), CD45R/B220 (Clone-RA3-6B2; BD Biosciences), CD3 (Clone-CD3-12; Bio-Rad), Ter119(Clon-TER119; BioLegend), and myeloperoxidase (Cat# A0398; Dako). Stained sections were scanned with Aperio AT2 digital slide scanner (Leica Biosystems) and stored in eSlide Image Management System (Leica Biosystems). The images were viewed with Aperio ImageScope software (Leica Biosystems).

2.5 | Cell culture and cell lines

Pre-T LBL(6605/4, 6645/4, 7298/2, 6781/3, 2883, 2696, 2641, and 2869) cell lines were established from single-cell suspensions and maintained as previously reported.9,17

2.6 | Sparse whole-genome sequencing

Copy number aberrations (CNAs) were determined by sparse whole-genome sequencing (WGS), as previously described.9 Briefly, 1 μg of genomic DNA was sonicated followed by end repair and A-tail addition and ligation of TruSeq adaptors. Libraries were pooled and sequenced, targeting 4 million reads per sample. Data analysis was performed as described previously,18 using higher resolution bin-boundaries, which allowed analysis of CNA at a segment resolution of ~125 kb (five consecutive bins for segmentation).

2.7 | Whole-exome sequencing

Data processing and variant calling procedure followed the Best Practices workflow recommended by the Broad Institute. Briefly, the raw sequencing reads were mapped to mouse genome build 10 (mm10) by the Burrows-Wheeler Aligner19 followed by local realignment using the GATK suite20 from the Broad Institute, and duplicated reads were marked by the Picard tools.

The somatic variants were first filtered with the GATK recommended filtering criteria and further filtered by the following criteria: Minimum fraction of altered reads 0.2; Minimum number of altered reads in a tumor ≥2; Log transformed FISHER p-value ≥1.5; Variant impact annotation from SnpEff effect prediction is “High” or “Moderate”; Exclude SNPs reported in dbSNP build 137 or previously identified as germline variants in the NIH C57BL/6 colony.

2.8 | PCR, Igh gene rearrangement, and Sanger sequencing

Genomic DNA was extracted from bone marrow (BM), spleen, thymus, and lymph node with DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s instruction. PCR was performed with HiFi Taq polymerase mix (Invitrogen) and primers (Invitrogen) as listed in Supporting Information Table S10. Scid primers were used as a housekeeping gene to assess DNA quality. Clonal Igh segments were identified using PCR-based
assays. RNA was extracted using TRIzol (Invitrogen) or RNeasy Mini Kit (Qiagen) with the manufacturer’s recommended protocols. cDNA was synthesized by reverse transcriptase using 1 µg RNA with SuperScript III First-Strand Synthesis System (Invitrogen) by reverse transcriptase-PCR (RT-PCR). cDNA quality was based on β-actin. Selected mutations identified by whole-exome sequencing (WES) were PCR amplified, purified, and confirmed by Sanger sequencing. Real-time quantitative PCR (RQ-PCR) was performed using SYBR Green PCR Master Kit (MilliporeSigma) and Taqman primer-probe (Mcm2; Mm00484815_m1, Ptpn1; Hs00942477_m1) sets with ABI Fast Universal PCR Master Mix on the ABI Fast7500 system (Applied Biosystems/Life Technologies). Samples were normalized to Gapdh or endogenous 18S rRNA with Eukaryotic 18S rRNA Endogenous Control (VIC) (Applied Biosystems). National Cancer Institute Sequencing MiniCore facility performed Sanger sequencing using purified DNA.

2.9 | Immunoblotting

Pellets of mouse embryonic fibroblasts (MEF) were lysed using RIPA Lysis Buffer (ChemCruz), containing phenylmethylsulfonyl fluoride, protease inhibitor, and sodium orthovanadate. The protein concentration was calculated using Micro BCA Protein Assay Kit (Thermo Fisher Scientific), and samples were prepared with Laemmli Sample Buffer (Bio-Rad). Twenty micrograms of protein was size-fractionated on 10% SDS-PAGE gels and transferred to nitrocellulose membrane (Thermo Fisher Scientific). After blocking membranes using 5% non-fat dry milk (Bio-Rad) in TBS with 0.1% Tween-20, immunoblotting was performed using the following primary and specific horseradish peroxidase (HRP)-conjugated antibodies and the manufacturer’s recommended concentration: ΜCM2 (Clone-EPR4120; Abcam), β-Actin (Clone-AC-15; Sigma), and Anti-rabbit/mouse IgG HRP-linked Antibody (Cat#7074/#7076; Cell Signaling). MCM2 protein was quantified by ImageJ software (US National Institutes of Health) and normalized against β-Actin.

2.10 | Transplantation and engraftment assay

Six-week-old female recipient mice which expressed the CD45.1 allele were purchased from the Jackson Laboratory. Μcm2Cre/Cre donor cells expressed the CD45.2 allele. The BM, LSK, or JK donor cells were derived from freshly dissected femora and tibiae from 5- to 6-week-old donor mice and transplanted into lethally irradiated (900cGy) recipient mice. Recipient mice were injected with 0.2 or 1×10E06 CD45.1-WT BM competitor cells and the following CD45.2-donor cells: WT LSK 3500 cells, WT BM 1 million cells, Mcm2Cre/Cre LSK 3500 cells, Mcm2Cre/Cre LK 26000 cells, Mcm2Cre/Cre;NHD13 BM 1 million cells. Peripheral blood engraftment and complete blood count (CBC) were assessed at 6, 12, 16, and 24 weeks after transplantation.

2.11 | Colony-forming unit assay

Thirty thousand primary BM cells per 35-mm Petri dish were plated in duplicate in Methocult GF M3434 medium (Stemcell Technologies), including the following cytokines; 50 ng/ml rm SCF, 10 ng/ml rmIL-3, 10 ng/ml rh IL-6, 3 units/ml rhEpo. The plates were incubated at 37°C in a 5% CO2 incubator, and the number of the colonies were counted on day7 (BFU-E).

2.12 | Statistics

Data are reported as mean values ± standard deviation. Statistical analysis was carried out with GraphPad Prism software ver 8.4.3 (GraphPad Software, LLC) using the Mantel–Cox log-rank test for Kaplan–Meier curve, unpaired Students’ t-test, and one-way ANOVA. Holm–Sidak correction of the unpaired Students test was used to correct for multiple hypothesis testing where indicated. p values < .05 were considered to be statistically significant.

3 | RESULTS

3.1 | Transplant of Mcm2Cre/Cre hematopoietic stem/progenitor cells (HSPCs) leads to severe anemia without malignant transformation

Given that the Mcm2Cre allele is a germline defect that results in decreased Mcm2 protein in mouse embry fibroblasts (MEFs) as well as thymocytes, we were surprised that we detected no malignancies other than pre-T LBL in Mcm2Cre/Cre mice. We considered the possibility that the aggressive, highly penetrant pre-T LBL that develops in Mcm2Cre/Cre mice kills the mice before an alternate, less aggressive malignancy of different histology has an opportunity to evolve. To test this hypothesis, we transplanted hematopoietic stem and progenitor cells (HSPCs) from Mcm2Cre/Cre mice into wild-type (WT) recipient mice, reasoning that the more differentiated Mcm2Cre/Cre HSPCs might generate myeloid malignancies, as opposed to the
thymic malignancies that are invariably produced in Mcm2<sup>Cre/Cre</sup> mice, and allow discovery of myeloid tumor suppressor genes.

Hematopoietic stem cells are found in a population of bone marrow cells which are negative for cell surface markers that mark commitment to a terminally differentiated cell lineage (Lineage negative), and are positive for the antigens Sca1 and Kit1; this population is abbreviated LSK. The Lineage<sup>−</sup>, Sca1<sup>−</sup>, Kit1<sup>(LK)</sup> population contains progenitor cells that are committed to a specific hematopoietic lineage (such as myeloid or erythroid), and under normal, non-malignant conditions are not self-renewing stem cells. LSK and LK populations were isolated from WT or Mcm2<sup>Cre/Cre</sup> bone marrow (BM) using fluorescence-activated cell sorting (FACS) and transplanted together with WT competitor cells into lethally irradiated 5-month-old WT recipients. (Supporting Information Figure S1A) The Mcm2<sup>Cre/Cre</sup> donor cells expressed the CD45.2 allele of CD45, whereas the WT competitor cells, and the WT recipients expressed the CD45.1 allele; CD45.1 and CD45.2 proteins can be distinguished by allele-specific CD45 antibodies.

Mice transplanted with LK cells from Mcm2<sup>Cre/Cre</sup> BM did not engraft, indicating that this population did not contain long-term self-renewing cells. However, LSK cells from Mcm2<sup>Cre/Cre</sup> BM were transplantable and self-renewing, and resulted in severe anemia, thrombocytopenia, and a trend toward neutropenia at 5 months’ post-transplant (Figure 1A). The mice were euthanized due to morbidity (hunched posture, tachypnea, lethargy) that was detected concurrent with the onset of severe anemia. There was no increase in blast percentage nor difference in myeloid, erythroid, T-, and B-cell proportions in BM from the Mcm2<sup>Cre/Cre</sup> LSK recipients compared to those of WT LSK recipients, suggesting that the peripheral blood cytopenias were not due to invasion of the BM with malignant cells (Supporting Information Figure S1B,C). In addition, parenchymal organs such as liver and spleen (SP) showed no loss of normal histology nor invasion of malignant cells (Supporting Information Figure S1D), in contrast to leukocytosis and invasion of parenchymal organs by leukemic cells previously seen in Mcm2<sup>Cre/Cre</sup> mice. Further analysis of Mcm2<sup>Cre/Cre</sup> LSK recipients demonstrated equivalent contribution of WT (CD45.1) and Mcm2<sup>Cre/Cre</sup> cells (CD45.2) in the BM (Supporting Information Figure S2A), with a similar distribution of myeloid, T, and B cells. However, there was a decreased contribution of erythroid cells (Ter119<sup>+</sup>CD71<sup>+</sup> and Ter119<sup>+</sup>CD71<sup>−</sup>) from the CD45.2 (Mcm2<sup>Cre/Cre</sup>) donor cells (Supporting Information Figure S2A,B). Peripheral blood (PB) showed persistent engraftment of T cells derived from Mcm2<sup>Cre/Cre</sup> cells, demonstrating that lack of malignancy was not due to lack of thymocyte engraftment or development (Figure 1B). Taken together, these results indicate that, in contrast to nearly universal leukemic transformation seen in Mcm2<sup>Cre/Cre</sup> transgenic mice, transplantation of Mcm2<sup>Cre/Cre</sup> LSK cells into WT recipients failed to cause leukemia, despite clear evidence of robust engraftment.

Having determined that the proximal cause of anemia in the Mcm2<sup>Cre/Cre</sup> LSK recipients was not due to infiltration with leukemic cells, we assessed other possible causes of the severe anemia seen in Mcm2<sup>Cre/Cre</sup> LSK recipients. The absolute number of BM cells was decreased by over 50% in the Mcm2<sup>Cre/Cre</sup> LSK recipients (Figure 1C). There was a marked decrease in the number of Mcm2<sup>Cre/Cre</sup>-derived erythroid cells compared to WT erythroid cells in the BM of Mcm2<sup>Cre/Cre</sup> LSK recipients (Figure 1D). Consistent with the decrease in Ter119<sup>+</sup>CD71<sup>+</sup> cells in the Mcm2<sup>Cre/Cre</sup> LSK BM, there was an absolute decrease in LSK cells and megakaryocyte-erythrocyte progenitors (MEP; Lin<sup>−</sup>Sca1<sup>−</sup>Kit<sup>−</sup>CD16/32<sup>−</sup>CD34<sup>+</sup>) (Figure 1E, Supporting Information Figure S2B) in the BM of Mcm2<sup>Cre/Cre</sup> LSK recipients. A functional colony-forming unit assay demonstrated decreased BFU-E colonies in secondary and tertiary plating from Mcm2<sup>Cre/Cre</sup> LSK recipients (Supporting Information Figure S2C). In sum, these findings suggest that the severe anemia in the Mcm2<sup>Cre/Cre</sup> LSK recipients was due to decreased HSPCs in the Mcm2<sup>Cre/Cre</sup> LSK recipients, most prominent in the erythroid lineage.

To rule out the possibility that the phenotype seen in Mcm2<sup>Cre/Cre</sup> LSK recipients could be due to the stress of sorting and ex vivo manipulation of the LSK cells, we co-transplanted 10<sup>5</sup> or 10<sup>6</sup> unmanipulated whole BM cells isolated from Mcm2<sup>Cre/Cre</sup> (CD45.2) mice and 10<sup>6</sup> whole BM competitor cells (CD45.1) into congenic CD45.1 recipients (n = 5 for each BM dose level). (Supporting Information Figure S3A) As controls, we transplanted 10<sup>6</sup> whole BM cells isolated from WT CD45.2 mice and 10<sup>6</sup> whole BM CD45.1 competitor cells (n = 5). Two recipients of 10<sup>5</sup> Mcm2<sup>Cre/Cre</sup> BM cells died 2 weeks post-transplant and showed no evidence of organomegaly at necropsy. All of the remaining mice showed evidence of engraftment at 6 weeks’ post-transplant (Supporting Information Table S1). However, the percent engraftment was markedly diminished in the Mcm2<sup>Cre/Cre</sup> recipients (Supporting Information Table S1 and Figure S3B), and further decreased throughout the observation period (with one exception, discussed below). Despite decreased engraftment, the Mcm2<sup>Cre/Cre</sup> recipients maintained normal PB counts for 12 weeks’ post-transplant. However, at 13–15 weeks’ post-transplant, five mice (all Mcm2<sup>Cre/Cre</sup> recipients) were unexpectedly found dead without organomegaly, and the experiment was terminated. At 15 weeks’ post-transplant, none of the three evaluable Mcm2<sup>Cre/Cre</sup>
recipients showed robust engraftment of non-malignant CD45.2 donor cells in PB, BM, or SP (Supporting Information Figure S3C), although M36 had engraftment of malignant CD45.2+ T-cells. Two Mcm2Cre/Cre recipients (M34, M38) showed profound pancytopenia with no evidence for malignancy (Supporting Information Table S1), and one Mcm2Cre/Cre recipient (M36) developed pre-T LBL (Supporting Information Figure S4). Finally, the absolute number of BM cells from Mcm2Cre/Cre recipients was decreased compared to WT (Supporting Information Figure S3D). These results indicated that Mcm2Cre/Cre hematopoietic cells lose self-renewal potential at ~15 weeks' post-transplant.

### 3.2 Decreased absolute number of HSPCs in Mcm2Cre/Cre mice

To determine if the decrease in BM cellularity seen in the Mcm2Cre/Cre HSPC transplant recipients was also present in non-transplanted Mcm2Cre/Cre mice, we evaluated HSPCs derived from 5-week-old Mcm2Cre/WT, Mcm2Cre/WT,
and $\text{Mcm2}^{\text{Cre/Cre}}$ mice. The numbers of unfractionated BM, LSK, and LK cells were all reduced in $\text{Mcm2}^{\text{Cre/Cre}}$ mice compared to the other two genotypes (Supporting Information Figure S5A,B). However, although the total number of HSPC was reduced in the $\text{Mcm2}^{\text{Cre/Cre}}$ mice, there was no significant decrease in MEP in $\text{Mcm2}^{\text{Cre/Cre}}$ compared to $\text{Mcm2}^{\text{Wt/Wt}}$. These findings suggest that hematopoiesis from $\text{Mcm2}^{\text{Cre/Cre}}$ mice is impaired and may be exaggerated by the stress of reconstitution imposed by bone marrow transplantation.

3.3 | Transplantation of LSK and LK cells from $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 mice leads to B-cell precursor acute lymphoblastic leukemia

Mice that express a NHD13 transgene develop MDS, which progresses to AML, or less commonly pre-T LBL or B-cell precursor acute lymphoblastic leukemia (BCP-ALL), in about 70% of mice. Since the NHD13 transgene predisposes mice to develop AML, we previously crossed the NHD13 transgene onto an $\text{Mcm2}^{\text{Cre/Cre}}$ background, reasoning that this strategy may uncover tumor suppressor genes important for AML. However all $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 mice developed pre-T LBL, and 26% of $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 mice developed a concurrent, independent BCP-ALL. Reasoning that committed hematopoietic progenitors would not be able to differentiate to thymocytes, we transplanted LK cells from a $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 donor into WT recipients, using uncommitted $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 LSK cells as a control. Recipients developed BCP-ALL with leukocytosis, anemia, and thrombocytopenia at 3–6 months of age (Figure 2A, Supporting Information Table S2). Flow cytometry (FCM) displayed expansion of abnormal B cells in BM, SP, thymus (TH), and lymph node (LN), as well as invasion into nonlymphoid tissues (Figure 2A,B). Analysis of $\text{Igh}$ gene configuration demonstrated monoclonal rearrangements in the leukemic cells (Supporting Information Figure S6A,B and Table S2); mice MT1180 and MT1183 had identical clonal $\text{Igh}$ rearrangements, suggesting these clones had a common ancestor. Although the conclusion is limited by the small number of recipient mice that we were able to analyze, these findings suggest that LSK and LK cells isolated from $\text{Mcm2}^{\text{Cre/Cre}}$;NHD13 mice did not induce pre-T LBL, but developed BCP-ALL rather than AML.

3.4 | $\text{Mcm2}^{\text{Cre/Cre}}, \text{Scid/Scid}$ mice failed to prevent pre-T LBL

We next chose an alternate approach to prevent pre-T LBL. We crossed $\text{Mcm2}^{\text{Cre/Cre}}$ onto a homozygous Prkdc$^{\text{Scid}}$ (hereafter, Scid) background, reasoning that Scid mice, deficient in both B and T lymphocytes, will not develop B- or T-cell malignancies, and therefore may develop AML. Mice with 2 alleles of Scid ($\text{Mcm2}^{\text{Cre/Cre}}, \text{Scid/Scid}$) were generated by crossing $\text{Mcm2}^{\text{Cre/Wt}}, \text{Scid/+}$. All $\text{Mcm2}^{\text{Cre/Cre}}, \text{Scid/Scid}$ mice developed pre-T LBL with a short life span (Supporting Information Figure S7A–C and Table S3). These pre-T LBL were characterized by differentiation to the DP stage of thymocyte development. The Scid allele is known to be somewhat “leaky,” and we hypothesized that a relatively rare thymocyte that differentiates beyond the DN stage is now susceptible to the highly penetrant, oncogenic influence of the $\text{Mcm2}^{\text{Cre/Cre}}$ genotype. The presence or absence of the Scid allele did not affect hemoglobin (Hgb) or platelet (Plt) counts (Supporting Information Figure S7D).

3.5 | $\text{Mcm2}^{\text{Cre/Cre}}$ nude (nu/nu) mice do not develop pre-T LBL, but instead develop BCP-ALL

Mice with two copies of the nude allele (nu/nu) lack mature T cells due to a mutated Foxn1 gene, which is required for the development of thymic epithelial cells. We reasoned that placing the $\text{Mcm2}^{\text{Cre/Cre}}$ alleles onto a nude background would prevent pre-T LBL, as nude mice have only a rudimentary thymic remnant and lack normal thymic development. Mice with $\text{Mcm2}^{\text{Cre/Wt}}$ and $\text{Mcm2}^{\text{Wt/Wt}}$ genotypes are phenotypically identical and not prone to malignancy or early death; similarly, mice with one copy of the nude allele have normal T cells and hair development. For simplicity, $\text{Mcm2}^{\text{Cre/Cre}}, \text{nu/+}$ and $\text{Mcm2}^{\text{Cre/Cre}}, +/+ +$ were pooled and designated $\text{Mcm2}^{\text{Cre/Cre}}$, and $\text{Mcm2}^{\text{Cre/Wt}}, \text{nu/nu}$ and $\text{Mcm2}^{\text{Wt/Wt}}, \text{nu/nu}$ were pooled and designated nu/nu. Finally, $\text{Mcm2}^{\text{Wt/Wt}}, +/+ +$, $\text{Mcm2}^{\text{Wt/Wt}}, \text{nu/+}$, $\text{Mcm2}^{\text{Cre/Wt}}, +/+ +$, and $\text{Mcm2}^{\text{Cre/Wt}}, \text{nu/+}$ were pooled and designated WT.

$\text{Mcm2}^{\text{Cre/Cre}}$ mice had a markedly decreased survival due to pre-T LBL, compared to WT mice (median, 80 days vs. not reached, $p < .001$) (Figure 3A, Supporting Information Figure S8A,B and Table S4). In contrast, $\text{Mcm2}^{\text{Cre/Cre}}, \text{nu/nu}$ mice did not develop pre-T LBL and had markedly prolonged survival compared to $\text{Mcm2}^{\text{Cre/Cre}}$, demonstrating that the lack of T-cell development in these mice prevents pre-T LBL and dramatically prolonged survival (Figure 3A). Despite a median survival of 296.5 days, >3X longer than $\text{Mcm2}^{\text{Cre/Cre}}$ mice, most $\text{Mcm2}^{\text{Cre/Cre}}, \text{nu/nu}$ mice eventually developed BCP-ALL characterized by anemia, thrombocytopenia, hepatomegaly, splenomegaly, and lymphadenopathy. Immunohistochemistry (IHC) and FCM demonstrated invasion of B220+ blasts in BM,
SP, TH, LN, and parenchymal tissues (Figure 3B,C and Supporting Information Table S4). Consistent with a diagnosis of BCP-ALL, the mice had clonal IgH gene rearrangements (Supporting Information Table S5). The immunophenotypes of these BCP-ALL were variable; some were CD19⁺B220⁻/low (e.g., D114 and D118 in Figure 3B), consistent with a pro-B1 ALL; others (e.g., D095, 556, and D567 in Figure 3B) were CD19⁺B220⁻ or CD19⁻B220⁺, more consistent with a pro-B2 ALL.

In addition to the leukemic mice described above, one Mcm2Cre/Cre;NHD13 HSPCs developed a solid ocular mass, with significant expansion of Mac-1⁺Gr-1⁺ in the liver or lung (Supporting Information Figure S9B), which suggested a chloroma-like disease. Three mice (D014, D049, and D302) died with profound anemia (Hgb 2.2–7.7 mg/dl) (Supporting Information Table S4) and decreased erythropoiesis in the BM, accompanied by erythroid expansion and maturation arrest in the spleen (Supporting Information Figure S9C). However, these three cases did not show peripheral leukocytosis, increased blasts in the BM, or infiltration of malignant erythroid cells in non-hematopoietic tissue (Supporting Information Figure S9D). Thus, the severe anemia seemed to be due to erythroid maturation arrest as opposed to myeloid leukemia.
Addition of an NP23 fusion gene accelerates onset of BCP-ALL in Mcm2Cre/Cre;nu/nu mice

We attempted to induce myeloid leukemias in Mcm2Cre/Cre;nu/nu mice using an (NUP98-PHF23 or NP23) transgene\textsuperscript{13} to promote AML. We crossed Mcm2\textsuperscript{Cre/Cre};nu/+ with Mcm2\textsuperscript{Cre/Cre};nu/+;NP23 to generate Mcm2\textsuperscript{Cre/Cre};nu/nu;NP23 mice. The NP23 transgene alone leads to early death from leukemia compared to WT mice (median, 248 days and not reached, p < .001) (Figure 4A). Placing the NP23 transgene on an Mcm2\textsuperscript{Cre/Cre} background...
had no effect on survival compared to Mcm2Cre/Cre; most mice developed an aggressive pre-T LBL (Supporting Information Table S6). Similar to Mcm2Cre/Cre, NHD13 mice, 27% (3/11) of the Mcm2Cre/Cre;NP23 mice developed BCP-ALL (Supporting Information Figure S10 and Table S6). The addition of the NP23 transgene to Mcm2Cre/Cre;nu/nu mice largely reversed the survival advantage seen in Mcm2Cre/Cre;nu/nu (median, 130.5 days vs 296.5 days, p < .001), and most Mcm2Cre/Cre;nu/nu;NP23 mice developed BCP-ALL. There was no clear difference between the Mcm2Cre/Cre;nu/nu and Mcm2Cre/Cre;nu/nu;NP23 BCP-ALL in terms of CBC, immunophenotype, or Ig V region usage (Supporting Information Tables S4–S7). Of note, similar to the previous characterization of pro-B1 ALL, 27 all the CD19+ B220−/low BCP-ALL in this study, utilized V segments located at the 3′ end of the V region cluster (Supporting Information Figure S11). A summary of leukemic phenotypes is shown in Supporting Information Figure S12.

### 3.7 NGS identification of recurrent, acquired mutations

We used sparse WGS to detect recurrent CNA (Figure 5). The minimal resolution of this technique is approximately 100 kb, and we previously found that most mutations identified by sparse WGS in pre-T LBL associated with Mcm2 deficiency were interstitial deletions of 100–1000 kb. We defined common deletions or gains to be those that occurred in at least two samples from mice with the Mcm2 hypomorph (Mcm2Cre/Cr;NHD13, Mcm2Cre/Cr;nu/nu or Mcm2Cre/Cr;nu/nu;NP23). In sum, we identified 24 recurrent CNA, most commonly deletions (Supporting Information Table S8). We identified no recurrent CNA in the erythroid hyperplasia samples. Note that the frequency of recurrent deleted regions is markedly less in mice with the Mcm2Cre/Wt;NHD13 genotype (1.25 CNA per tumor; Supporting Information Table S8), which would be expected to have WT Mcm2 function. Recurrently deleted regions encompassed numerous genes that are well known to be inactivated in human B-cell malignancies, including Pax5, Ikzf3, Nf1, and Sh2b3. High-resolution views show that important tumor suppressor genes are often the only gene present within a commonly deleted region. (Figure 5B,C) In addition, we have previously shown that Bcor, although not frequently mutated in human B-cell malignancies, was frequently inactivated via single-nucleotide variation (SNV) or small indel in murine pro-B1 ALL; focal Bcor deletions were identified in all three Mcm2Cre/Cr genotype groups in this study (Supporting Information Figure S13A). Similarly, DNMT3a, which is commonly mutated in human myeloid malignancies but not in human B-cell malignancy, was recurrently deleted. Finally, Ptpn1, although not commonly mutated in human B-cell malignancies, was recurrently deleted in all 3 Mcm2Cre/Cr genotypes (Supporting Information Figure S13B). We confirmed that the recurrent Ptpn1 deletions were associated with decreased Ptpn1 expression by qRT-PCR (Supporting Information Figure S13C).

We used WES to detect small indels and SNVs associated with the development of BCP-ALL in Mcm2Cre/Cr;nu/nu and Mcm2Cre/Cr;nu/nu;NP23 mice. We identified recurrent Tier 1 mutations in genes known or suspected to be involved in B-cell malignancy, such as Ikzf3, Pax5, and Bcor (Supporting Information Table S9). We identified non-recurrent (i.e., only one example) mutations in genes well known to be involved in B-cell malignancy, including Kras, Tp53bp1, Ptpn11, and Notch1. Figure 6 shows an integrated summary of genotype, immunophenotype, WES, and sparse WGS findings with respect to genes known or suspected to be involved in B-cell malignancies and B-cell differentiation. Several genes, such as Sh2b3 or Nf1, were shown to be inactivated via either SNV or large interstitial deletion, whereas other genes (Jak1, Kras, and Ptpn11) were only mutated via SNV missense mutation, and others (Ptpn1, Ebf1, and Pax5) only mutated via large interstitial deletion. As noted previously, as opposed to B-cell leukemia that developed in mice with an Mcm2Cre/Cr genotype which universally showed CNA involving relevant genes, the B-cell leukemia that developed in mice with an Mcm2Cre/Wt genotype had no evidence of recurrent, focal CNA.

Taken together, these integrated findings demonstrate that most BCP-ALL samples contained mutations in one or more pathways known to be critical determinants for human B-cell malignancies, such as impaired B-cell differentiation, increased stem cell self-renewal, hyperproliferation, and cytokine-independent growth, and that the most common form of oncogenic mutation in mice with the Mcm2Cre/Cr genotype are recurrent interstitial deletions of 100–1000 kb.

### 3.8 MEFs from Mcm2Cre/Cr mice do not display a deleter phenotype

We considered the possibility that the failure to detect nonlymphoid malignancies in Mcm2Cre/Cr mice may be due to a less severe “deleter” phenotype in nonlymphoid tissues. To test this possibility, we established MEFs from Mcm2W/W, Mcm2Cre/W, and Mcm2Cre/Cr mice. Given that we planned to examine MEFs that had been passed in vitro, we first verified that the Mcm2 protein deficiency present in Mcm2Cre/Cr pre-T LBL persisted after passage in vitro. Since no pre-T LBL malignancies developed in
**FIGURE 4**  
*Mcm2*<sup>Cre/Cre</sup>*;nu/nu;NP23* mice develop BCP-ALL. (A) Survival of *Mcm2*<sup>Cre/Cre</sup>*;nu/nu;NP23* and control genotypes. **p < .01, ***p < .001, ****p < .0001. (B) Immunophenotype of *Mcm2*<sup>Cre/Cre</sup>*;nu/nu;NP23* BCP-ALL (D935, D956, D021, D050, and 591), demonstrate a range of CD19 and B220 expression (compare Figure 3B). (C) H&E and B220 staining of *Mcm2*<sup>Cre/Cre</sup>*;nu/nu;NP23* B-ALL (591) demonstrates invasion of lung, liver, and BM with B220+ cells. Scale bar, 1 mm; inset 200 μm.
Figure 5: Sparse WGS analysis of B-cell leukemias. (A) Whole-genome view of CNA; gains are shown in red, and losses are shown in blue. Boundaries of CNA are highlighted in gray. The color intensity is (log2) proportional to the degree of gain or loss. (B) Whole-chromosome (upper) and high-resolution (lower) view of recurrent Pax5 losses. (C) Whole-chromosome (upper) and high-resolution (lower) view of recurrent Sh2b3 losses.
Mcm2<sub>Wt/Wt</sub> or Mcm2<sub>Cre/Cre</sub> mice, we used pre-T LBL cell lines established from SCL/LMO1 mice<sup>17</sup> as controls. Supporting Information Figure S14A shows that the growth rates of the SCL/LMO1 cell lines were similar to the Mcm2<sub>Cre/Cre</sub> cell lines, and that the decreased mRNA and protein in Mcm2<sub>Cre/Cre</sub> cell lines persisted in vitro (Supporting Information Figure S14B,C).

Similar to the findings with Mcm2<sub>Cre/Cre</sub> pre-T LBL cell lines, Mcm2<sub>Cre/Cre</sub> MEFs showed ~20% as much Mcm2 mRNA and protein as Mcm2<sub>Wt/Wt</sub> MEFs, demonstrating persistence of the Mcm2 protein deficiency in vitro (Supporting Information Figure S15A,B). We considered the possibility that interstitial deletions might occur in fibroblasts but are not identified in bulk genomic DNA because MEFs are polyclonal (in contrast to the clonal expansion of lymphoid malignancies with recurrent CNA). Therefore, we isolated single-cell clones from Mcm2<sub>Wt/Wt</sub>, Mcm2<sub>Cre/Wt</sub>, and Mcm2<sub>Cre/Cre</sub> MEFs (Supporting Information Figure S15C) and analyzed five clones of each genotype by sparse WGS analysis as shown.
in Supporting Information Figure S15D. There are very few CNA in any clones and no difference in the number or region of CNA correlated with MEF genotype. Small CNA may not be visibly apparent at the whole-genome survey level shown in Supporting Information Figure S15D. Higher resolution at the individual chromosome level was analyzed, and again no recurrent deletions were identified in the MEF samples. Supporting Information was analyzed, and again no recurrent deletions were identified in the MEF samples. Supporting Information Figure S15E,F show high-resolution views of genes commonly deleted in BCP-ALL (Ptpn1) and pre-T LBL (Pten), respectively.

4 | DISCUSSION

We and others have previously shown that mice deficient for Mcm proteins are prone to chromosomal abnormalities and consequent malignancies. In particular, mice with an Mcm2 hypomorphic allele develop pre-T LBL early in life due to recurrent interstitial deletions of critical tumor suppressor genes. Interestingly, despite the fact that the Mcm2 hypomorph is a germline defect, the only malignancies we could document in Mcm2<sup>Cre/Cre</sup> mice on a C57BL/6 background were pre-T LBL. One factor that has been reported to be relevant for tumor development in other Mcm mutant mouse models is the mouse strain background; for instance, Mcm4<sup>Chaos3/Chaos3</sup> mice develop mammary tumors on a C3H background, but primarily show perinatal lethality and microphthalmia on a C57BL/6 background.

Interestingly, a different Mcm4 mutation (Mcm4<sup>D573H</sup> as opposed to Mcm4<sup>Chaos3/Chaos3</sup>) leads to pre-T LBL on a mixed C57BL/6 × FVB/N or C57BL/6 × 129S1/SvImJ background. An additional possibility for the thymus specificity of the Mcm2<sup>Cre/Cre</sup> malignancies is that a tissue with rapidly dividing cells, such as the thymus, has increased susceptibility to this unique “deleter” phenotype. We hypothesized that if the Mcm2<sup>Cre/Cre</sup> cells were “protected” from pre-T LBL, that they may develop alternate forms of malignancy due to deletion of other, tissue-restricted tumor suppressor genes, such as Apc or Brca1.

Although Mcm2<sup>Cre/Cre</sup> LK cells did not engraft, Mcm2<sup>Cre/Cre</sup> LSK cells engrafted with normal hematopoietic PB indices until 5 months’ post-transplant, at which time the mice became clinically ill with anemia, thrombocytopenia, and borderline neutropenia. Analysis of HSPC showed decreased long-term hematopoietic stem cell (LT-HSC) and MEP populations; similar results were subsequently obtained with a transplant of unfractionated Mcm2<sup>Cre/Cre</sup> BM. Analysis of young (we were limited to studying mice younger than 6 weeks of age for pre-T LBL cells begin to infiltrate Mcm2<sup>Cre/Cre</sup> BM by this age) Mcm2<sup>Cre/Cre</sup> BM similarly demonstrated decreased LT-HSC and MEP in the Mcm2<sup>Cre/Cre</sup> mice. We conclude that the Mcm2 hypomorph leads to failure of HSPC at approximately 5 months of age, which is obscured by the pre-T LBL that generally emerges by 3 months of age. The decreased number and early failure of LT-HSC and MEP in the Mcm2<sup>Cre/Cre</sup> mice is similar to findings with an Mcm3 hypomorph, which showed neonatal erythroid failure and poor engraftment of Mcm3-deficient HSC, and we speculate that this hematopoietic failure is due to cumulative replicative stress.

Given that homozygous Scid mice have a marked decrease in the number of T and B cells, we predicted that placing the Mcm2<sup>Cre</sup> allele on homozygous Scid background might protect the mouse from developing pre-T LBL, and allow them to live past the 3- to 4-month lifespan, at which point they may develop other forms of malignancy. However, all Mcm2<sup>Cre/Cre,Scid/Scid</sup> mice developed pre-T LBL with age of onset slightly earlier than Mcm2<sup>Cre/Cre</sup> mice. Although somewhat surprising, the Scid defect is known to be leaky, and prior crosses of thymic oncogenes onto a Scid background had resulted in pre-T LBL, albeit at later onset. In addition, Scid/Scid mice are known to be sensitive to ionizing radiation due to defective NHEJ caused by the mutant Prkdc<sup>Scid</sup> allele; therefore, it is possible that Mcm2<sup>Cre/Cre,Scid/Scid</sup> mice may have a higher mutation burden and earlier onset of pre-T LBL than Mcm2<sup>Cre/Cre</sup> mice.

Nude (nu/nu) mice lack mature T cells due to Foxn1 deficiency, which leads to dysfunction of thymic epithelial cells. All Mcm2<sup>Cre/Cre,nu/nu</sup> mice were protected from developing T-cell malignancy, and had a median life span of 296 versus 80 days. We suspect that the failure of Mcm2<sup>Cre/Cre,nu/nu</sup> mice to develop a T-cell malignancy is due to the fact that nu/nu mice lack T cells. In contrast to Scid/Scid mice, nu/nu was maintained on an inbred nu/nu background. Therefore, it remains possible that the failure to develop T-cell malignancy is independent of the Foxn1 deficiency and is instead due to an unchanged strain difference between C57BL/6 and nu/nu mice. Despite this more prolonged survival, most Mcm2<sup>Cre/Cre,nu/nu</sup> mice developed BCP-ALL.

Three Mcm2<sup>Cre/Cre,nu/nu</sup> mice developed severe anemia without evidence of leukemic transformation; this observation is reminiscent of the severe anemia that developed in the Mcm2<sup>Cre/Cre</sup> LSK transplant experiment; we speculate that similar to the transplant experiment, the longer survival uncovers the HSC and erythroid failure phenotype. Intriguingly, a subset of the BCP-ALL samples had a CD19<sup>+</sup>B220<sup>−/low</sup> phenotype, which is consistent with a B1 lymphocyte progenitor. Leukemias of B1-progenitor origin have recently been described and are characterized by skewed utilization of VH segments during VDJ recombination, with preferential usage of VH segments at the 3′ end of the VH<sub>1</sub> region. To date, ALL of progenitor B1 origin has only been described in the context of an NP23 transgene and Bcor mutation; the current study demonstrates that pro-B1 ALL can occur in other genetic contexts as well.
We used sparse WGS and WES to compare and contrast acquired mutations in the B-cell malignancies that arose in different genetic backgrounds (Figure 6). As anticipated based on results obtained with pre-T LBL,9 interstitial deletions involving important tumor suppressor genes were common events in Mcm2Cre/Cre BCP-ALL, whereas only one gene (Pax5) was recurrently deleted in Mcm2Cre/Wt mice. These results support the hypothesis that the Mcm2 hypomorph leads to recurrent interstitial deletions. These recurrent deletions involved several known tumor suppressor genes such as Pax5, Bcor, Ikkζ3, Nf1, Srcap, and Pten. Pax5 is one of the most commonly mutated genes in human BCP-ALL,40 and IKZF3, Nf1, and PTEN are also recurrently mutated in human BCP-ALL.29 BCOR (for BCL6 corepressor) is frequently mutated in human leukemias and lymphoma, including AML, MDS, and pre-T LBL.41–43 Although BCOR is rarely mutated in human B-lineage malignancy, they are detected in human B-cell lymphomas,44 and acquired inactivating mutations were seen in over 90% of murine pro-B1 ALL.27 Srcap deletions were identified in over 20% of the BCP-ALL samples. Although SRCAP deletions are not common in human B-cell malignancies, SRCAP has recently been identified as a gene implicated in hematopoietic stem cell differentiation that is frequently mutated in human MDS and clonal hematopoiesis.45,46 Finally, Ptpn1 was frequently deleted in Mcm2Cre/Cre BCP-ALL. Although PTNP1 mutations are not common in human B-cell malignancies, the recurrent and focal nature of these deletions leads us to suspect that Ptpn1 may be a tumor suppressor gene in BCP-ALL.

In addition to the deletions identified by sparse WGS, we identified additional acquired mutations, primarily SNV and small indels, through WES. Most prominent were monoallelic gain of function mutations involving signaling molecules well known to be involved in human B-cell malignancies such as Jak1,47 Kras,29,48 and Ptpn1.48,49 In addition, Sh2b3 and Nf1, two genes known to be recurrently mutated in human BCP-ALL,29 were found to have both interstitial deletions and SNV, suggesting that these genes may be inactivated by either deletion or point mutations. As shown in Figure 6, most BCP-ALL that occurred in Mcm2Cre/Cre,nu/nu mice had at least one mutation in each of three pathways (B-cell differentiation, kinase and signaling, and stem cell differentiation) that have been shown to be important for human BCP-ALL, indicating that the Mcm2Cre/Cre,nu/nu mice serve as an excellent model that recapitulates all of the key features of human BCP-ALL. Of note, Mcm2Cre/Cre;NHD13 mice can also serve as a reproducible model for human BCP-ALL,50 with acquired mutations that overlap with those of the Mcm2Cre/Cre,nu/nu mice, but these are generated through a more cumbersome bone marrow transplant model.

Despite the fact that the Mcm2Cre/Cre allele is a germ-line defect, when Mcm2Cre/Cre mice were protected from developing pre-T LBL, the only clear malignancy that developed was BCP-ALL. Notably, T and B lymphocytes are both programmed to tolerate the DNA DSB and acquired 100–1000kb interstitial deletions that occur during normal VDJ recombination which produces mature antigen receptor genes (T-cell receptors and immunoglobulins, respectively).51 We considered the possibility that recurrent interstitial deletions were common in other tissues from Mcm2Cre/Cre mice, but were not detectable as there was no malignancy, and no clonal expansion of nonlymphoid cells or tissues, and hypothetical polyclonal interstitial deletions went undetectable. To address this hypothesis, we searched for recurrent interstitial deletions in single-cell clones established from Mcm2Cre/Cre, Mcm2Cre/Wt, and Mcm2Wt/Wt MEFs, but identified no recurrent interstitial deletions in MEFs from any genotype. T and B lymphocytes are unique in that they are the only mammalian cell types that normally undergo programmed interstitial deletions, during the process of RAG-mediated VDJ recombination which generates mature antigen receptor genes (T-cell receptors and immunoglobulins). Although speculative, it is possible that T and B lymphocytes, which are programmed to undergo interstitial deletions, are able to tolerate DNA DSB induced by the Mcm2 hypomorph, whereas non-lymphocytes undergo apoptosis due to DNA DSB induced by the Mcm2 hypomorph.

In sum, we show that the protection of Mcm2Cre/Cre mice from developing pre-T LBL, through transplantation of committed hematopoietic cells or a modified genetic background, uncovers a previously undocumented failure of hematopoiesis, and reveals a susceptibility to B-cell malignancy. The BCP-ALL that develops in Mcm2Cre/Cre;nu/nu mice closely resembles human BCP-ALL in terms of immunophenotype and the spectrum of acquired mutations. We suggest that Mcm2Cre/Cre mice might serve as a general model for producing deletions of tumor suppressor genes in vivo, if cells can be programmed to tolerate DNA DSB and interstitial deletions, similar to T and B lymphocytes.

AUTHOR CONTRIBUTIONS
Peter D. Aplan, Toshihiro Matsukawa, and Mianmian Yin conceived and designed the project. Toshihiro Matsukawa, Mianmian Yin, Timour Baslan, Dengchao Cao, Yang Jo Chung., Yuelin J. Zhu., and Robert L. Walker performed experiments, and Toshihiro Matsukawa, Mianmian Yin, Timour Baslan, Ryan Bertoli, Yuelin J. Zhu, Robert L. Walker, and Peter D. Aplan analyzed the data. Amy Freeland and Erik Knudsen established Mcm2 MEFs. Toshihiro Matsukawa wrote the manuscript draft. All authors reviewed, edited, and approved the manuscript.
ACKNOWLEDGMENTS
The authors thank current and former members of the Aplan laboratory for insightful discussions. We thank the NCI Sequencing Minicore for Sanger sequencing, the NCI Flow cytometry core for cell sorting, the NCI Pathology/ Histotechnology Lab (PHL) for IHC, the NCI Transgenic Core for generation of transgenic mice, and Maria Jorge for excellent animal husbandry. This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health (to Peter D. Aplan, grant numbers ZIA SC0130378, SC010379), The Naito Foundation (to Toshihiro Matsukawa), and The Uehara Memorial Foundation (to Toshihiro Matsukawa), and the William C. and Joyce C. O’Neil Charitable Trust, Memorial Sloan Kettering Single Cell Sequencing Initiative (to Timour Baslan).

DISCLOSURES
Peter D. Aplan receives royalties from NIH Office of Technology Transfer for the invention of NHD13 mice.

DATA AVAILABILITY STATEMENT
Mouse strains NHD13, NP23, Mmc2Cre are available from the authors. Nude (nu/nu) and Scid mice are available from Jackson Labs. The WES data that support the findings of this study are available in SRA with the identifier (https://dataview.ncbi.nlm.nih.gov/object/PRJNA799024?reviewer=5ijd6ml6cu7i48e34qjbe0l8g) (PRJNA799024).

ORCID
Toshihiro Matsukawa https://orcid.org/0000-0003-2371-3778
Peter D. Aplan https://orcid.org/0000-0001-5686-9969

REFERENCES

**SUPPORTING INFORMATION**
Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Matsukawa T, Yin M, Baslan T, et al. Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. *The FASEB Journal*. 2022;36:e22430. doi:10.1096/fj.20220061RR